secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001193125-24-177016
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger sells Avexitide to Amylyx for $35.1M in bankruptcy sale closed July 9
---------------------------------------------------------------------------

- Sold Avexitide asset to Amylyx Pharmaceuticals for $35.1M plus assumed cure costs and liabilities.
- Bankruptcy Court approved sale on June 26, 2024; transaction closed July 9, 2024.
- Amylyx will handle development, manufacturing, and commercialization of Avexitide.
- Eiger's common stock (EIGRQ) trades on OTC Pink; company cautions of potential total loss for securityholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/0001193125-24-177016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/d861769d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-177016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer